Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power (TCORS-1)
Cardiovascular Risk Factor, Nicotine Dependence
About this trial
This is an interventional basic science trial for Cardiovascular Risk Factor focused on measuring E-Cigarettes, Vaping, E-Cig Mods
Eligibility Criteria
Inclusion Criteria:
- Use e-cigarettes on at least 25 days in the past 30 for at least 3 months and have not used another tobacco product in the past 30 days
- Healthy on the basis of medical history and limited physical examination (screening visit), as described below:
- Heart rate < 105 beats per minute (BPM)*
- Systolic Blood Pressure < 160 and > 90*
- Diastolic Blood Pressure < 100 and > 50*
Body Mass Index (BMI) ≤ 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues)
*Considered out of range if both machine and manual readings are above/below these thresholds.
- Any race/ethnicity
Exclusion Criteria:
- Used tobacco products other than e-cigarettes in past 30 days
- Expired carbon monoxide of over 5 ppm at screening
- The following unstable medical conditions:
- Heart disease
- Uncontrolled hypertension
- Thyroid disease (not hypo or hyper, controlled with medication)
- Diabetes
- Hepatitis B or C or Liver disease
- Glaucoma
- Prostatic hypertrophy
- Psychiatric conditions:
- Current or past schizophrenia, and/or current or past bipolar disorder
- Adult onset attention deficit hyperactivity disorder (ADHD) (if being treated)
- Participants with current or past depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion
- Psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
- Drug/Alcohol Dependence:
- Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
- Positive toxicology test at the screening visit (THC & prescribed medications okay)
- Opioid replacement therapy
- Positive urine cannabis is not exclusionary but participant must report use of cannabis in any form on not more than 2 times per week to be eligible
- Psychiatric medications:
- Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) and serotonin-norepinephrine reuptake Inhibitor (SNRIs) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate.
- Medications
- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, dexamethasone, phenobarbital, and other anticonvulsant drugs).
- Concurrent use of nicotine-containing medications
- Other/Misc. Chronic Health Conditions
- Oral thrush
- Fainting
- Untreated thyroid disease
- Other "life threatening illnesses" as per study physician's discretion
- Pregnancy
- Pregnancy (self-reported and urine pregnancy test)
- Breastfeeding (determined by self-report)
- Concurrent participation in another clinical trial
- Inability to communicate in English
- Planning to quit smoking or vaping within the next 60 days
Sites / Locations
- Zuckerberg San Francisco General Hospital
- University of California, San Francisco
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Power level 10, 15, or 20 watts
1 of the other 2 remaining power levels
Remaining power level
Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of 3 assigned battery power levels
Using an electronic cigarette, the patient will participate in a standardized vaping session using 1 of the other 2 remaining power levels
Using an electronic cigarette, the patient will participate in a standardized vaping session using the remaining power level